3SOF

Catching a bounce....

Volume: 732,400
Avg Vol (3m): 325,879

Technicals
Close Below the 13-day EMA
Percentage Gainer

Last Price Quote is:
-3.72%below 13-day EMA
24.74%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm

Nice candlestick today,Long White candlestick or White Marubozu...
Today a White Marubozu was formed. This shows that the buyers controlled the price action from the first trade to the last trade.
The last two candlesticks formed a Bullish Engulfing Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires
confirmation

Support @ $1.74...1.57...1.23
Resistance @ $1.83...2.21...2.55

Shares of tiny Questcor Pharmaceuticals (amex: QSC) jumped 11%. Andrew McDonald of ThinkEquity Partners reiterated a "buy" rating and $4 price target on the stock.

"With Indiplon being kept off the shelves, we believe Questcor's ability to successfully market Doral (quazepam) to neurologists increases significantly," he said. "Doral, a long-acting benzodiazepine for insomnia, will be the only marketed agent in its class when Questcor begins detailing the product in the third quarter of this year."

Technicals
Percentage Gainer
Stochastic is Bullish
Last Price Quote is:
-3.00%below 13-day EMA
4.17%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm

Up today......+0.19 (+16.24%) close @ $1.36 HOD

52wk Range: 0.70 - 2.64
Volume: 503,900
Avg Vol (3m): 87,467.2

Technicals
Close Above the 50-day MA ...........
Close Above the 13-day MA ........
Percentage Gainer

Last Price Quote is:
10.12%above 13-day MA
1.39%above 50-day MA
RS Rating: 5 

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm



UNION CITY, Calif., Dec 04, 2006 (BUSINESS WIRE) -- James L. Fares, President and CEO of Questcor Pharmaceuticals, Inc. (QSC, Trade), will give a company update at the BMO Capital Markets Focus on Healthcare 2006 Investor Conference. The conference will be held at the Millennium Broadway Hotel, 145 West 44th Street in New York City. Mr. Fares will make his presentation on Thursday, December 7 at 8:45 am EST.

The presentation will be webcast and is accessible at the following link, http://www.bmocm.com/conferences/healthcare2006 or by visiting Questcor's website, where the presentation will be archived for up to two weeks following the event, at www.questcor.com.

About Questcor -- Questcor Pharmaceuticals, Inc.(R) (QSC, Trade) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with multiple sclerosis and Doral(R) (quazepam), that is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

SOURCE: Questcor Pharmaceuticals, Inc.


Questcor Pharmaceuticals, Inc. 
Eric Liebler, 510-400-0740 
[email protected] 

Copyright Business Wire 2006 ********************************************************************** As of Thursday, 11-30-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 05-11-2006 for QSC @ $1.72. For more information on Comtex SmarTrend? Alert, contact your market data provider or go to www.CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2006 Comtex News Network, Inc. All rights reserved.

Press Release Source: Questcor Pharmaceuticals, Inc.


Questcor Board Approves New Strategy and Business Model for H.P. Acthar Gel
Monday August 27, 6:30 am ET


UNION CITY, Calif.--(BUSINESS WIRE)--Questcor Pharmaceuticals, Inc. (AMEX:QSC - News) announced today that its Board of Directors has approved a new strategy and business model for H.P. Acthar Gel®, a natural form of adrenocorticotropic hormone (ACTH). This change may affect the usage of Acthar in the treatment of certain diseases, including multiple sclerosis (MS) and infantile spasms (IS), an extremely rare form of epilepsy. Specifically, Questcor will initiate a new pricing model, create an expanded safety net for patients using Acthar, and provide a group of Medical Science Liaisons to work with health care providers who are administering Acthar.


Don M. Bailey, Questcor's Interim President commented, "the goal of Questcor's new strategy is to make manufacturing and distribution of Acthar economically viable on a stand-alone basis, so that Questcor can continue to ensure the availability of Acthar for those patients who need it most and fund projects which can contribute to the growth of the company."

Acthar is currently approved in the U.S. for the treatment of MS exacerbations and other conditions. No drug is approved in the U.S. for the treatment of IS, a potentially life-threatening disorder that typically begins in the first year of life. However, pursuant to guidelines published by the American Academy of Neurology and the Child Neurology Society, many child neurologists use Acthar to treat infants afflicted with this condition. In June 2006 Questcor submitted a Supplemental New Drug Application to the Food and Drug Administration (FDA) and is currently pursuing formal agency approval for Acthar in the treatment of IS. Previously, the FDA granted Orphan Designation to H.P. Acthar Gel for the treatment of IS. As a result of this Orphan Designation, if Questcor is successful in obtaining FDA approval for the IS indication, Questcor will also qualify for a seven year exclusivity period during which FDA is prohibited from approving any other ACTH formulation for IS unless the other formulation is demonstrated to be clinically superior to Acthar. Questcor anticipates incurring significant additional costs in its further pursuit of a formal FDA-approved indication for Acthar in the treatment of IS.

The implementation of this new strategy includes a change in the method of distribution for Acthar and a significant increase in treatment cost. In addition, Questcor has changed its support program for health care professionals and reinforced its safety net for patients using Acthar. Questcor previously announced that the change in distribution from multiple distributors to a single specialty distributor is complete. Acthar is now being distributed only through its specialty distributor, Curascript. This new distribution system provides seamless support for Acthar including providing necessary information to health care providers and families, assisting with reimbursement, and distributing product faster. As of the end of July, this transition had virtually eliminated all Acthar inventories held by wholesalers. The new pricing is effective Monday, August 27 and brings Acthar in line with the cost of treatments for other very rare diseases. Based on Questcor's understanding of the usage of Acthar, the cost for a course of treatment could approach $80,000-$100,000.

Questcor acquired Acthar in 2001. Since then, to ensure that this drug remains available on a consistent basis for the patients who need it, Questcor has incurred significant costs to transfer and modernize Acthar's complex manufacturing process to assure continued compliance with FDA standards. Questcor net losses were $10.1 million in 2006 and $5.5 million for the first six months of 2007.

Questcor's new strategy is intended to create an economic model that will allow Questcor to support ongoing efforts to manufacture and distribute Acthar, to conduct any FDA-required studies, to continue development of QSC-001, and to develop or acquire other drugs or drug candidates for neurological disorders or for rare diseases.

Questcor continues to focus on the need to work with patients who are attempting to secure reimbursement from their insurance companies and has expanded its participation with the National Organization for Rare Disorders (NORD), an advocacy group for patients afflicted with rare disorders and a sponsor of patient assistance and co-pay assistance programs for patients who are otherwise unable to afford their treatments. The combination of the change to a specialty distributor, the availability of Medical Science Liaisons, the expanded participation with NORD, and existing government programs -- Medicaid and the federally-funded State Children's Health Insurance Program -- is intended to provide a safety net to make Acthar available to all patients who need it.

New Risk Factor

Questcor's implementation of this new pricing model creates risks and uncertainties for Questcor, including risks associated with the possibility of lower unit sales, the refusal of third-party payors to provide reimbursement for purchases of Acthar, and the financial impact of the return to Questcor or sale to third parties of previously sold product. Questcor could receive negative publicity as a result of its adoption of this new strategy, and responding to inquiries from the press or patient advocacy groups, or dealing with litigation against Questcor, could divert the attention of key employees from operating Questcor's business. Other risks and uncertainties are discussed below under "About Questcor."

About Infantile Spasms

Infantile spasms(IS) is a life threatening seizure disorder of early childhood also known as West Syndrome. The onset is predominantly in the first year of life, typically between three to six months. The typical pattern of IS is a sudden bending forward and stiffening of the body, arms, and legs; although there can also be arching of the torso. Spasms tend to begin soon after arousal from sleep. Individual spasms typically last for one to five seconds and occur in clusters, ranging from 2 to 100 spasms at a time. Infants may have dozens of clusters and several hundred spasms per day. Infantile spasms usually stop by age 5, but are often replaced by other seizure types. Infantile spasms are characterized by seizures, hypsarrhythmia (abnormal, chaotic brain wave patterns), and mental retardation. Other neurological disorders, such as cerebral palsy, may be seen in 30-50% of those with IS. The incidence of IS is estimated to be about 1 per 2,000 to 4,000 live births. It is the most frequent type of epileptic encephalopathy, the group of conditions in which epilepsy determines cognitive deterioration. No drug is currently approved in the United States for the treatment of IS. Patients diagnosed with this disorder are typically treated with a variety of agents, including Acthar.

About H.P. Acthar Gel

H.P. Acthar Gel® is a natural adrenocorticotropic hormone (ACTH) designed to provide a prolonged release after intramuscular or subcutaneous injection. Acthar is currently indicated for the treatment of a wide range of conditions with an inflammatory component, like acute exacerbations of multiple sclerosis, various types of arthritis and ulcerative colitis. For full prescribing information and safety information on Acthar, please visit http://www.acthar.com.

About Questcor

Questcor Pharmaceuticals, Inc® (AMEX:QSC - News) is a specialty pharmaceutical company that develops and commercializes therapeutics for the treatment of neurological disorders. Questcor's products include H.P. Acthar® Gel (repository corticotropin injection) and Doral® (quazepam), which is indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to successfully implement a new strategy for Acthar, Questcor's ability to identify and hire a permanent Chief Executive Officer, Questcor's ability to accurately forecast the demand for its products, the gross margin achieved from the sale of its products, Questcor's ability to enforce its product returns policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell-through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's potential future need for additional funding, Questcor's ability to utilize its net operating loss carry forwards to reduce income taxes on the sale of its non-core products, research and development risks, uncertainties regarding Questcor's intellectual property and the uncertainty of receiving required regulatory approvals in a timely way, or at all, other research, development, and regulatory risks, and the ability of Questcor to acquire products and, if acquired, to market them successfully and find marketing partners where appropriate, as well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2006 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Contact:
Questcor Pharmaceuticals, Inc.
Don Bailey or Steve Cartt, 510-400-0700
[email protected]

--------------------------------------------------------------------------------
Source: Questcor Pharmaceuticals, Inc.

Took a long haul down, may be ready to turn the tide...
Back above the 13 and 50-day MA, looks as if the 13 may be ready to cross over the 50-day.

52wk Range: 0.21 - 1.89
Volume: 698,800
Avg Vol (3m): 140,230

Technicals
Close Above the 50-day MA
Percentage Gainer

Last Price Quote is:
38.58%above 13-day MA
30.95%above 50-day MA
RS Rating: 42 

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/08/2007
Last Analyst Rating: NT/LT Mkt Outprfm

Quote from: setravis on August 28, 2007, 09:21:30 PM
Took a long haul down, may be ready to turn the tide...
Back above the 13 and 50-day MA, looks as if the 13 may be ready to cross over the 50-day.

Turn the tide she did ! We have the "Golden Cross" !!
Potential/fundamentals improved, sales increasing.

Recent CandleStick Analysis
Very Bullish
Nov-09-2007 Bullish Engulfing 

Support @ $1.49...1.38...1.33
Resistance @ $2.23...2.64
MACD is Bullish

52wk Range: 0.21 - 1.89
Volume: 7,594,550
Avg Vol (3m): 303,192

Technicals
Record Price High
Most Actives
Record Price Break Out
Percentage Gainer

Last Price Quote is:
49.32%above 13-day MA
95.90%above 50-day MA
RS Rating: 99 

Fundamentals
Earnings Surprise
Reports Earnings

Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm


Below are the 6 month and 3 year charts.......

Questcor Reports Third Quarter Results
Now Cash Flow Positive from Operations.........
* Third quarter earnings per share $0.12
* Third quarter sales $14.8 million



bizjournals.com
Questcor Pharmaceuticals posts Q3 profit
Monday November 12, 1:37 pm ET


Questcor Pharmaceuticals Inc. Monday reported a third-quarter profit after the company implemented a new business model focusing on its core product, H.P. Acthar Gel.
Union City-based Questcor (AMEX: QSC - News) reported sales of 14.8 million for the third quarter, compared with $4 million in sales in the year-ago quarter.

The company had net income of $8.6 million, or 12 cents per share, for the quarter, compared with a loss of $1.5 million, or a loss of 3 cents per share, a year ago.

Published November 12, 2007 by the East Bay Business Times

Busted through the resistance @ $2.64...


52wk Range: 0.21 - 2.23
Volume: 5,083,550
Avg Vol (3m): 420,795

Technicals
Record Volume
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
104.42%above 13-day MA
178.19%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm

Questcor swings to Q3 profit  !
Getting some action.......

Questcor Pharmaceuticals Inc. reported a profit of $8.6 million for the third quarter.
The Union City company (AMEX: QSC) lost $1.5 million in the same quarter a year ago.

Sales of the company's H.P. Acthar Gel drug for multiple sclerosis related conditions pushed it to a profit. Questcor recorded $14.6 million in sales of the drug during the quarter, making up the lion's share of the company's third quarter revenue of $14.8 million.

A year ago Questcor had sales of $4 million in the third quarter.

The company is also developing a pain drug, which it hopes to put into clinical trials next year.




52wk Range: 0.21 - 3.29
Volume: 3,824,400
Avg Vol (3m): 570,439

Technicals
Record Volume
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
146.14%above 13-day MA
270.25%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm

Updated look,

Friday's closing chart.......

man!, I wish I would have been following this one!
but take a look at this-
QSC   insider baught 2,446,782 shares at 4.68/share which equates to $11,450,939 on 11/20/2007
something should be getting ready to happen if this many shares were baught don't you think?

Quote from: pinoleropuro on November 29, 2007, 07:44:33 AM
man!, I wish I would have been following this one!
but take a look at this-
QSC   insider baught 2,446,782 shares at 4.68/share which equates to $11,450,939 on 11/20/2007
something should be getting ready to happen if this many shares were baught don't you think?

Getting some action........
A pharmaceutical company that focuses on novel therapeutics for the treatment of diseases and disorders of the central nervous system.

More than Momentum, this stock is rising for a reason !
Momentum times four.......
Pharmaceutical firm Questcor Pharmaceuticals easily takes the momentum prize this week for an incredible rise of nearly 330%. The small cap's surge in revenue from its multiple sclerosis drug in the most recent quarter sent shares north and led to $8.4 million in net income for the firm.  Investors are still divided on the long-term prospects of Questcor, however, with one-fourth of the investors rating the company an underperform against the broader market.

Ultimately, the only story that counts is your own. Whether you buy the story of a soaring or a souring stock, your own research is more important than collective opinions. But these collective opinions make an individual's due diligence much easier. 

52wk Range: 0.21 - 5.18
Volume: 4,192,650
Avg Vol (3m): 964,266

Technicals
Record Price High
Most Actives
Percentage Gainer

Fundamentals
Key Data:
Market Cap (M): $26.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: NT/LT Mkt Outprfm

UNION CITY, Calif., Nov 29, 2007 (BUSINESS WIRE) -- Questcor Pharmaceuticals, Inc. (QSC, Trade) announced today that Don M. Bailey, 61, has been appointed President and Chief Executive Officer. Prior to this appointment, Mr. Bailey was the Interim President of the Company, a role in which he has served since May of 2007.

"Don's been instrumental in setting the foundation for Questcor's strategic redirection announced in August. Under his leadership as our interim president, Questcor is now profitable and generating positive cash flows after a history of operating losses. As our new Chief Executive Officer, Don will continue to implement this new strategy and pursue other strategies that seek to generate shareholder value," said Virgil Thompson, Questcor's Chairman of the Board. "We welcome Don as our new Chief Executive Officer and we look forward to his continued leadership at Questcor."

Mr. Bailey joined Questcor's Board of Directors in May 2006. Mr. Bailey is currently the non-executive Chairman of the Board of STAAR Surgical Company, a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies. Mr. Bailey served as Chairman of the Board of Comarco, Inc., a provider of wireless test products for the wireless industry and a maker of emergency call box systems and mobile power products for handheld devices from 1998 to August 2007. He also served from June 1990 to April 2000 as President and Chief Executive Officer of Comarco, Inc., where he was employed since May 1980. He earned a B.S. in mechanical engineering from the Drexel Institute of Technology in 1968, a M.S. degree in operations research from the University of Southern California in 1971 and an MBA from Pepperdine University in 1986.

About Questcor - Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two commercial products, H.P. Acthar(R) Gel ("Acthar") and Doral(R), and is developing new medications using strategies that generally require lower capital investment when compared to traditional development programs. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS"). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing new medications, including QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to continue to successfully implement the new strategy and business model for Acthar, Questcor's ability to accurately forecast the demand for its products, the gross margin achieved from the sale of its products, Questcor's ability to enforce its product returns policy, Questcor's ability to estimate the quantity of Acthar used by government entities and Medicaid eligible patients, that the actual amount of rebates and discounts related to the use of Acthar by government entities and Medicaid eligible patients may differ materially from Questcor's estimates, the sell-through by Questcor's distributors, the expenses and other cash needs for upcoming periods, the inventories carried by Questcor's distributors, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's potential future need for additional funding, Questcor's ability to utilize its net operating loss carry forwards to reduce income taxes on taxable income, research and development risks, uncertainties regarding Questcor's intellectual property and the uncertainty of receiving required regulatory approvals in a timely way, or at all, other research, development, and regulatory risks, and the ability of Questcor to acquire products and, if acquired, to market them successfully and find marketing partners where appropriate, as well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2006 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: Questcor Pharmaceuticals, Inc.


Questcor Pharmaceuticals, Inc. 
Don Bailey or Steve Cartt, 510-400-0700 
[email protected] 
or 
EVC Group, Inc. 
Investors: 
Doug Sherk, 415-896-6820 
Julie Huang, 646-443-6963 
Media: 
Julie Huang, 646-443-6963 

Copyright Business Wire 2007

Applaud travis.  This has been on fire!

New high of 6.49.....
http://www.americanbulls.com/StockPage.asp?CompanyTicker=QSC&MarketTicker=AMEX&TYP=S